AIM ImmunoTech releases investor video on Ampligen's potential for Ebola preparedness
AIM ImmunoTech released a virtual investor video discussing Ampligen's potential application in treating Bundibugyo Ebola virus disease, highlighting preclinical research showing 100% protective survival in mouse models. The company emphasizes the unmet medical need for targeted therapies against this Ebola strain and positions Ampligen as a potential prophylactic or early-onset therapeutic candidate.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day